Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-13-052519
Filing Date
2013-10-03
Accepted
2013-10-03 21:18:53
Documents
1
Period of Report
2013-10-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 rrd392210.html 4  
1 FORM 4 rrd392210.xml 4 21638
  Complete submission text file 0001181431-13-052519.txt   23024
Mailing Address 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080
Business Address 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 650-266-0000
ONYX PHARMACEUTICALS INC (Issuer) CIK: 0001012140 (see all company filings)

EIN.: 943154463 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O ONYX PHARMACEUTICALS, INC. 2100 POWELL ST., 12TH FLOOR EMERYVILLE CA 94608
Business Address
Fust Matthew K (Reporting) CIK: 0001397266 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-28298 | Film No.: 131135360